We are live on ! Find out more
OAM

Oberweis Asset Management Portfolio holdings

AUM $3.39B
1-Year Est. Return 105.5%
This Fund
S&P 500
This Quarter Est. Return
+11.11%
1 Year Est. Return
+105.5%
3 Year Est. Return
+311.52%
5 Year Est. Return
+632.9%
10 Year Est. Return
+11,604.3%
AUM
$2.73B
AUM Growth
+$123M
Cap. Flow
+$6.55M
Cap. Flow %
0.24%
Top 10 Hldgs %
20.79%
Holding
204
New
21
Increased
104
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$20.7M
2
GMED icon
Globus Medical
GMED
+$20.5M
3
DAN icon
Dana Inc
DAN
+$16.9M
4
SGHC icon
SGHC Ltd
SGHC
+$15.3M
5
CNR
Core Natural Resources Inc
CNR
+$15.2M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$39.8M
2
SRAD icon
Sportradar
SRAD
+$37.1M
3
ITRI icon
Itron
ITRI
+$35.4M
4
LRN icon
Stride
LRN
+$27.1M
5
QRVO icon
Qorvo
QRVO
+$23.8M

Sector Composition

Rank Sector Weight
1 Technology 37.24%
2 Healthcare 19.19%
3 Industrials 17.15%
4 Consumer Discretionary 13.69%
5 Financials 4.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIR icon
76
Mirion Technologies
MIR
$3.77B
$14.2M 0.52%
+607,800
New +$15.2M
CVLT icon
77
Commault Systems
CVLT
$5.59B
$13.9M 0.51%
110,900
-17,700
-14% -$2.49M
RELY icon
78
Remitly
RELY
$5.42B
$13.8M 0.51%
1,002,800
– –
CPRX
79
DELISTED
Catalyst Pharmaceutical
CPRX
$13.7M 0.5%
586,970
+58,410
+11% +$1.3M
LASR icon
80
nLIGHT
LASR
$3.38B
$13.4M 0.49%
356,400
+90,400
+34% +$3.02M
LIVN icon
81
LivaNova
LIVN
$4.19B
$13.1M 0.48%
212,300
+26,300
+14% +$1.5M
DAVE icon
82
Dave Inc
DAVE
$4.58B
$13M 0.48%
58,922
+13,300
+29% +$2.86M
HQY icon
83
HealthEquity
HQY
$8.67B
$13M 0.47%
141,580
+1,500
+1% +$144K
CALX icon
84
Calix
CALX
$2.39B
$12.9M 0.47%
+244,600
New +$14.2M
KNSA icon
85
Kiniksa Pharmaceuticals
KNSA
$6.03B
$12.9M 0.47%
312,800
+7,600
+2% +$305K
COCO icon
86
Vita Coco
COCO
$3.64B
$12.4M 0.45%
233,400
+5,100
+2% +$239K
ZWS icon
87
Zurn Elkay Water Solutions
ZWS
$8.57B
$12.4M 0.45%
266,000
– –
EZPW icon
88
Ezcorp Inc
EZPW
$1.75B
$12.2M 0.45%
627,900
-57,600
-8% -$1.09M
TILE icon
89
Interface
TILE
$2.24B
$12.2M 0.44%
435,800
+10,500
+2% +$286K
SKWD icon
90
Skyward Specialty Insurance
SKWD
$2.59B
$12.1M 0.44%
237,500
+5,700
+2% +$274K
ADPT icon
91
Adaptive Biotechnologies
ADPT
$3.9B
$12.1M 0.44%
744,500
+18,000
+2% +$294K
MD icon
92
Pediatrix Medical
MD
$2.19B
$12M 0.44%
559,987
+14,387
+3% +$295K
ABCB icon
93
Ameris Bancorp
ABCB
$5.88B
$11.6M 0.42%
156,400
– –
FN icon
94
Fabrinet
FN
$20.7B
$11.5M 0.42%
25,200
-20,700
-45% -$9M
LQDA icon
95
Liquidia Corp
LQDA
$8.06B
$11.4M 0.42%
329,200
+8,000
+2% +$228K
TPB icon
96
Turning Point Brands
TPB
$1.73B
$11.2M 0.41%
103,500
+2,500
+2% +$244K
AXGN icon
97
Axogen
AXGN
$2.4B
$11M 0.4%
336,200
+8,100
+2% +$199K
WK icon
98
Workiva
WK
$3.46B
$11M 0.4%
+127,500
New +$11.3M
MTDR icon
99
Matador Resources
MTDR
$5.97B
$10.8M 0.39%
253,900
– –
AGX icon
100
Argan
AGX
$8.55B
$10.3M 0.38%
32,971
-27,600
-46% -$8.76M
2 3
4
5 6

Similar funds

BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
VFCM
Valley Forge Capital Management Miami, Florida $3.38B AUM 15.93% 1-Year Est. Return
MCM
Marsico Capital Management Denver, Colorado $3.4B AUM 51.58% 1-Year Est. Return
EFM
E Fund Management Guangzhou, China $3.37B AUM
DIA
Dana Investment Advisors Waukesha, Wisconsin $3.35B AUM 29.65% 1-Year Est. Return
5NCM
59 North Capital Management Houston, Texas $3.35B AUM 22.14% 1-Year Est. Return
QCG
Quadrant Capital Group Cincinnati, Ohio $3.34B AUM 29.16% 1-Year Est. Return

Oberweis Asset Management's Q4 2025 Portfolio in Review

As of Q4 2025, Oberweis Asset Management held 204 positions worth $2.73B, up 4.7% from $2.61B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Oberweis Asset Management's Q4 2025 filing shows 21 new, 104 increased, 20 reduced and 25 closed positions. Its largest new stake was Arcutis Biotherapeutics: 808,400 shares worth $23.5M. The largest sale was ADMA Biologics, an estimated $39.8M.

By sector, the portfolio is most concentrated in Technology at 37% of assets, down from 41% a quarter earlier, followed by Healthcare and Industrials.

  • Oberweis Asset Management's largest Q4 2025 buy was Arcutis Biotherapeutics: 808,400 shares worth $23.5M.
  • Oberweis Asset Management added most to Alphatec Holdings in Q4 2025, an estimated $9.98M increase.
  • Oberweis Asset Management's biggest Q4 2025 reduction was Lumentum, cutting an estimated $12.3M.
  • Oberweis Asset Management fully exited ADMA Biologics in Q4 2025, selling an estimated $39.8M.
  • Oberweis Asset Management's ten largest holdings make up 21% of its $2.73B portfolio in Q4 2025.
  • Oberweis Asset Management opened 21 new positions and closed 25 in Q4 2025.
  • Oberweis Asset Management's portfolio value rose 4.7% quarter-over-quarter to $2.73B.

Based on Oberweis Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.